Elevance Health, Inc. (NYSE:ELV) entered into an agreement to acquire Paragon Healthcare, Inc. on January 4, 2024. After the acquisition closes, Paragon Healthcare will operate as part of CarelonRx, the pharmacy services segment within Carelon, Elevance Health?s health services division. The acquisition is subject to customary closing conditions and is expected to close in the first half of 2024; it is not expected to have a material impact on adjusted earnings per share in 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
553.1 USD | +4.24% | +4.52% | +17.30% |
07-15 | Truist Securities Adjusts Price Target on Elevance Health to $620 From $600, Maintains Buy Rating | MT |
07-11 | 50 billion dollars - What US insurers pocketed for fictitious illnesses |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.30% | 123B | |
+13.44% | 94.15B | |
-13.59% | 46.3B | |
-6.87% | 35.22B | |
-14.94% | 16.64B | |
-19.31% | 2.76B | |
+14.63% | 1.72B | |
+81.70% | 784M |
- Stock Market
- Equities
- ELV Stock
- News Elevance Health, Inc.
- Elevance Health, Inc. entered into an agreement to acquire Paragon Healthcare, Inc.